This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pasireotide, long acting repeatable (Signifor) for acromegaly – first and second line

< Back

Pasireotide, long acting repeatable (Signifor) for acromegaly – first and second line


Endocrine, Nutritional and Metabolic

December 2010

Pasireotide long-acting repeatable (LAR) (SOM230, Signifor) is a novel multireceptor ligand somatostatin (sst) analogue with a high affinity binding profile for sst1, sst2, sst3 and sst5 receptor subtypes, mimicing the action of natural sst. Receptor subtypes sst2 and sst5 are expressed in 90% of GH-secreting pituitary tumours and once activated signal the pituitary gland to suppress GH secretion1. Pasireotide LAR also exhibits antiangiogenic activity (inhibiting vascular endothelial growth factor [VEGF] secretion) and works to reduce both the incidence and volume of pituitary tumours 2. Pasireotide LAR is intended to treat acromegaly first or second line and is administered as an intramuscular (IM) depot injection. In trials it has been administered at a dose of between 20 and 60mg every 28 days.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts